Category: Johnson & Johnson
J&J subsidiary Lifescan asks the courts to ban Shasta from using its logo, saying problems with Shasta's products are harming the Lifescan brand.
Johnson & Johnson (NYSE:JNJ) subsidiary Lifescan took its trademark gripe with Shasta Technologies to a California judge, saying the company's use of their logo is harming the Lifescan brand.
Johnson & Johnson subsidiary Biosense Webster enrolls its 1st patient in the reMARQable clinical study evaluating the nMARQ pulmonary vein isolation system in treatment of paroxysmal atrial fibrillation.
A federal judge overseeing a raft of cases filed against Johnson & Johnson's DePuy Orthopaedics subsidiary over its Pinnacle hip implants orders the medical device company to provide compliance monitoring reports to the plaintiffs' lawyers.
Shares of Johnson & Johnson are up 40% over the past year, but the rally hasn't accompanied strong, even financial performance, especially from its struggling medical device segment.
By Stephen Simpson
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-metal hip implants effective August 31, citing slowing sales and new FDA classification.
Johnson & Johnson (NYSE:JNJ) is pulling the plug on its troubled metal-on-metal hip implant business, effective August 31.
